Early, Nondisabling Parkinson's Disease: Weighing the Options for Initial Therapy

Neurologic Clinics

Volumn 26, Issue 3 SUPPL., 2008, Pages 1-13

  Silver, Dee E ^a  

^a Coastal Neurological Medical Group Inc ^*  (United States)

Author keywords

[No Author keywords available]

Indexed keywords

AMANTADINE; AMPHETAMINE; ANTIDEPRESSANT AGENT; ANTIPARKINSON AGENT; APOMORPHINE; BENZATROPINE; BROMOCRIPTINE; CARBIDOPA; CHOLINERGIC RECEPTOR BLOCKING AGENT; DEXTROMETHORPHAN; DOPAMINE RECEPTOR STIMULATING AGENT; ENTACAPONE; ERGOLINE DERIVATIVE; IODINE 123; LEVODOPA; MONOAMINE OXIDASE B INHIBITOR; MONOAMINE OXIDASE INHIBITOR; OPIATE; PERGOLIDE; PETHIDINE; PLACEBO; PRAMIPEXOLE; PROFENAMINE; RASAGILINE; ROPINIROLE; ROTIGOTINE; SELEGILINE; SEROTONIN UPTAKE INHIBITOR; TRIHEXYPHENIDYL; UNINDEXED DRUG;

ADJUVANT THERAPY; AGITATION; AKINESIA; ANXIETY; APPLICATION SITE REACTION; BLURRED VISION; BRADYKINESIA; CARDIAC VALVE REGURGITATION; CLINICAL FEATURE; CLINICAL TRIAL; CLOSED ANGLE GLAUCOMA; COGNITIVE DEFECT; COMBINATION CHEMOTHERAPY; COMPULSION; CONFUSION; CONTROLLED CLINICAL TRIAL; CONTROLLED DRUG RELEASE; DAILY LIFE ACTIVITY; DAYTIME SOMNOLENCE; DIAPHORESIS; DIARRHEA; DISEASE COURSE; DISEASE SEVERITY; DIZZINESS; DOSE RESPONSE; DRUG CONTRAINDICATION; DRUG DELIVERY SYSTEM; DRUG DOSE COMPARISON; DRUG DOSE INCREASE; DRUG DOSE REDUCTION; DRUG DOSE TITRATION; DRUG EFFICACY; DRUG HALF LIFE; DRUG MECHANISM; DRUG MEGADOSE; DRUG METABOLISM; DRUG WITHDRAWAL; DYSKENESIA; DYSKINESIA; FEVER; HALLUCINATION; HEADACHE; HUMAN; HYPERREFLEXIA; IDIOPATHIC DISEASE; IMPULSIVENESS; INCOORDINATION; INSOMNIA; LEG EDEMA; LIVEDO RETICULARIS; LOW DRUG DOSE; MEMORY DISORDER; MENTAL CONCENTRATION; MENTAL HEALTH; MONOTHERAPY; MORNING DOSAGE; MOTOR DYSFUNCTION; MOTOR FLUCTUATION; MYOCLONUS; NAUSEA; NERVOUSNESS; NONHUMAN; ORTHOSTATIC HYPOTENSION; PARKINSON DISEASE; POSITRON EMISSION TOMOGRAPHY; PRIORITY JOURNAL; QUALITY OF LIFE; RANDOMIZED CONTROLLED TRIAL; RECOMMENDED DRUG DOSE; RESTLESSNESS; REVIEW; RIGIDITY; RISK ASSESSMENT; SCORING SYSTEM; SEDATION; SEROTONIN SYNDROME; SHIVERING; SIDE EFFECT; SINGLE PHOTON EMISSION COMPUTER TOMOGRAPHY; SLEEP DISORDER; SOCIAL STATUS; SOMNOLENCE; THERAPY DELAY; TREATMENT DURATION; TREATMENT OUTCOME; TREMOR; UNSPECIFIED SIDE EFFECT; URINE RETENTION; VALVULAR HEART DISEASE; XEROSTOMIA;

ANTIPARKINSON AGENTS; DISABILITY EVALUATION; EARLY DIAGNOSIS; HUMANS; PARKINSON DISEASE;

EID: 50649125228     PISSN: 07338619     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.ncl.2008.05.004     Document Type: Review

References (54)

1. Chase T.N. The significance of continuous dopamine stimulation in the treatment of Parkinson's disease. Drugs 55 Suppl 1 (1998) S1-S9
2. Chase T.N., and Oh J.D. Striatal dopamine and glutamate-mediated dysregulation in experimental Parkinsonism. Trends Neurosci 23 Suppl 10 (2000) S86-S91
3. Bédard M.A., Lemay S., Gagnon J.F., et al. Induction of a transient dysexecutive syndrome in Parkinson's disease using a subclinical dose of scopolamine. Behav Neurol 11 4 (1998) 187-195
4. Perry E.K., Kilford L., Lees A.J., et al. Increased Alzheimer pathology in Parkinson's disease related to antimuscarinic drugs. Ann Neurol 54 2 (2003) 235-238
5. Katzenschlager R., Sampaio C., Costa J., et al. Anticholinergics for symptomatic management of Parkinson's disease. Cochrane Database Syst Rev 2 (2003) CD003735
6. Schrag A., Schelosky L., Scholz U., et al. Reduction of Parkinsonian signs in patients with Parkinson's disease by dopaminergic versus anticholinergic single-dose challenges. Mov Disord 14 2 (1999) 252-255
7. Marjama-Lyons J., and Koller W. Tremor-predominant Parkinson's disease. Approaches to treatment. Drugs Aging 16 4 (2000) 273-278
8. Aoke F.Y., and Sitar D.S. Clinical pharmacokinetics of amantadine hydrochloride. Clin Pharmacokinet 14 1 (1988) 35-51
9. Schwab R.S., England Jr. A.C., Poskanzer D.C., et al. Amantadine in the treatment of Parkinson's disease. JAMA 208 7 (1969) 1168-1170
10. Schwab R.S., Poskanzer D.C., England Jr. A.C., et al. Amantadine in Parkinson's disease. Review of more than two years' experience. JAMA 222 7 (1972) 792-795
11. Danielczyk W. Twenty-five years of amantadine therapy in Parkinson's disease. J Neural Transm Suppl 46 (1995) 399-405
12. Butzer J.F., Silver D.E., and Sahs A.L. Amantadine in Parkinson's disease. A double-blind, placebo-controlled, crossover study with long-term follow-up. Neurology 25 7 (1975) 603-606
13. Uitti R.J., Rajput A.H., Ahlskog J.E., et al. Amantadine treatment is an independent predicator of improved survival in Parkinson's disease. Neurology 46 6 (1996) 1551-1556
14. Vollum D.I., Parkes J.D., and Doyle D. Livedo reticularis during amantadine treatment. Br Med J 2 5762 (1971) 627-628
15. Sladden M.J., Nicolaou N., Johnston G.A., et al. Livedo reticularis induced by amantadine. Br J Dermatol 149 3 (2003) 656-658
16. Silver D.E., and Sahs A.L. Livedo reticularis in Parkinson's disease patients treated with amantadine hydrochloride. Neurology 22 7 (1972) 665-669
17. Reynolds G.P., Elsworth J.D., Blau K., et al. Deprenyl is metabolized to methamphetamine and amphetamine in man. Br J Clin Pharmacol 6 (1978) 542-544
18. Parkinson's Study Group. Effect of deprenyl on the progression of disability in early Parkinson's disease. N Engl J Med 321 (1989) 1364-1371
19. Myllyla V.V., Sotaniemi K.A., Vuorinen J.A., et al. Selegiline as initial treatment in de novo parkinsonian patients. Neurology 42 2 (1992) 339-343
20. Mally J., Kovacs A.B., and Slone T.W. Delayed development of symptomatic improvement by (-)-deprenyl in Parkinson's disease. J Neurol Sci 134 1-2 (1995) 143-145
21. Palhagen S., Heinonen E.H., Hägglund J., et al. Selegiline delays the onset of disability in de novo Parkinsonian patients. Swedish Parkinson Study Group. Neurology 51 2 (1998) 520-525
22. Tetrud J.W., and Langston J.W. The effect of deprenyl (selegiline) on the natural history of Parkinson's disease. Science 45 (1989) 519-522
23. Palhagen S., Heinonen E., Hagglund J., et al. Selegiline slows the progression of the symptoms of Parkinson's disease. Neurology 66 (2006) 1200-1206
24. Heinonen E.H., and Myllyla V. Safety of selegiline (deprenyl) in the treatment of Parkinson's disease. Drug Safety 19 (1998) 11-22
25. Youdim M.B., and Riederer P.F. A review of the mechanisms and role of monoamine oxidase inhibitors in Parkinson's disease. Neurology 63 (2004) S32-S35
26. Youdim M.B., Gross A., and Finberg J.P. Rasagiline [N-propargyl-1R(+)-aminoindan], a selective and potent inhibitor of mitochondrial monoamine oxidase B. Br J Pharmacol 132 (2001) 500-506
27. Parkinson Study Group. A controlled trial of rasagiline in early Parkinson's disease. Arch Neurol 59 12 (2002) 1937-1943
28. Parkinson Study Group. A controlled, randomized, delayed-start study of rasagiline in early Parkinson disease. Arch Neurol 61 4 (2004) 561-566
29. DeMarcaida J.A., Schwid S.R., White W.B., et al., Parkinson Study GroupTEMPOPRESTO Tyramine Substudy Investigators and Coordinators. Effects of tyramine administration in Parkinson's disease patients treated with selective MAO-B inhibitor rasagiline. Mov Disord 21 (2006) 1716-1721
30. Goetz C.G., Schwid S.R., Eberly S.W., et al., and the Parkinson Study Group, TEMPO and PRESTO Investigators. Safety of rasagiline in elderly patients with Parkinson's disease. Neurology 66 9 (2006) 1427-1429
31. Parkinson Study Group. Dopamine transporter brain imaging to assess the effects of pramipexole vs levodopa on Parkinson disease progression. JAMA 287 (2002) 1653-1661
32. Baseman D.G., O'Suilleabhain P.E., Reimold S.C., et al. Pergolide use in Parkinson's disease is associated with cardiac valve regurgitation. Neurology 63 (2004) 301-304
33. Tintner R., Manian P., Gauthier P., et al. Pleuropulmonary fibrosis after long-term treatment with the dopamine agonist pergolide for Parkinson disease. Arch Neurol 62 (2005) 1290-1295
34. Waller E.A., Kaplan J., and Heckman M.G. Valvular heart disease in patients taking pergolide. Mayo Clin Proc 80 (2005) 1016-1020
35. Silver D.E. Impact of functional age on the use of dopamine agonist in patients with Parkinson's disease. Neurologist 12 (2006) 214-223
36. Olanow C.W., Watts R.L., and Koller W.C. An algorithm for the management of Parkinson's disease. Neurology 15 Suppl (1998) 133
37. Poewe W. Should treatment of Parkinson's disease be started with a dopamine agonist?. Neurology 51 Suppl 2 (1998) S21-S24
38. Adler C.H., Sethi K.D., Hauser R.A., et al. Ropinirole for the treatment of early Parkinson's disease. Neurology 49 (1997) 393-399
39. Rascol O., Brooks D.J., Korczyn A.D., et al. A five-year study of the incidence of dyskinesia in patients with early Parkinson's disease who were treated with ropinirole or levodopa. 056 Study Group. N Engl J Med 342 (2000) 1484-1491
40. Rascol O., Brooks D.J., Korczyn A.D., et al. Development of dyskinesias in a 5-year trial of ropinirole and L-dopa. Mov Disord 21 (2006) 1844-1850
41. Parkinson Study Group. Pramipexole vs. levodopa as initial treatment for Parkinson disease: a 4-year randomized controlled trial. Arch Neurol 61 (2004) 1044-1053
42. Parkinson Study Group. Pramipexole vs. levodopa as initial treatment for Parkinson disease. JAMA 284 (2000) 1931-1938
43. Whone A.L., Watts R.L., Stoessl A.J., et al. Slower progression of Parkinson's disease with ropinirole versus levodopa: the REAL-PET study. Ann Neurol 54 (2003) 93-101
44. Samanta J.E.S., and Stacy M. Pathologic gambling in Parkinson's disease. Mov Disord 15 Suppl 3 (1998) 111
45. Pfeiffer R.F. A promising new technology for Parkinson's disease. Neurology 65 Suppl 1 (2005) S6-S10
46. Jankovic J., Watts R.L., Martin W., et al. Transdermal rotigotine-double-blind, placebo-controlled trial in Parkinson disease. Arch Neurol 64 (2007) 676-682
47. Giladi N., Boroojerdi B., Korczyn A.D., et al. Rotigotine transdermal patch in early Parkinson's: a randomized, double-blind controlled study versus placebo and ropinirole. Mov Disord 22 (2007) 2398-2404
48. Olanow C.W., and Koller W.C. An algorithm for the management of Parkinson's disease: treatment guidelines. American Academy of Neurology. Neurology 50 Suppl 3 (1998) S1-S57
49. Poewe W.H., Lees A.J., and Stern G.M. Low-dose L-dopa therapy in Parkinson's disease: a 6-year follow-up study. Neurology 36 11 (1986) 1528-1530
50. Blin J., Bonnet A.M., and Agid Y. Does levodopa aggravate Parkinson's disease?. Neurology 38 9 (1988) 1410-1416
51. Fahn S., Oakes D., Shoulson I., et al. Levodopa and the progression of Parkinson's disease. N Engl J Med 351 24 (2004) 2498-2508
52. Fahn S., and and the Parkinson Study Group. Does levodopa slow or hasten the rate of progression of Parkinson's disease?. J Neurol 252 Suppl 4 (2005) IV37-IV42
53. Ravina B., Eidelberg D., Ahlskog J.E., et al. The role of radiotracer imaging in Parkinson's disease. Neurology 64 2 (2005) 208-215
54. Ahlskog J.E., and Muenter M.D. Frequency of levodopa-related dyskinesias and motor fluctuations as estimated from the cumulative literature. Mov Disord 16 3 (2001) 448-458